Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 4/20 | 0.35 |
| ▸ | HTT | P42858 | 2/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 4/20 | 0.33 |
| ▸ | TP53 | P04637 | 3/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TSHR | P16473 | 6/20 | 0.33 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | RECQL | P46063 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | ALPL | P05186 | 1/20 | 0.32 |
| ▸ | ALPI | P09923 | 1/20 | 0.32 |
| ▸ | ALPG | P10696 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29799844 | 1.00 | GAA (0.35) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL535004 | 0.91 | GAA (0.33) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL29280983 | 0.89 | GAA (0.32) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL15728332 | 0.86 | GAA (0.32) | GAAHTTMAPTNPSR1ALDH1A1 | |
| SCHEMBL29799735 | 0.84 | EDNRA (0.40) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL6694770 | 0.84 | EDNRA (0.40) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL26688761 | 0.84 | EDNRA (0.40) | GAAHTTPOLBMAPTTP53 | |
| SCHEMBL30296047 | 0.82 | EDNRB (0.42) | GAAMAPTTP53ALDH1A1 | |
| SCHEMBL29281002 | 0.82 | TSHR (0.34) | GAAHTTPOLBCYP3A4CYP2C9 | |
| SCHEMBL6985496 | 0.81 | MAPT (0.34) | GAAHTTPOLBCYP3A4CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117836294-A | Biological antagonist containing aromatic ring, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2024-04-05 | — | — | CN | disclosed |
| CN-117085013-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-21 | — | — | CN | disclosed |
| CN-117017985-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-10 | — | — | CN | disclosed |
| CN-116983302-A | Biphenyl sulfonamide compounds useful for treating kidney diseases or conditions | 特拉维尔治疗公司 | 2023-11-03 | — | — | CN | disclosed |
| WO-2023066348-A1 | DUAL ANTAGONIST AND USE THEREOF | 年衍药业（上海）有限公司 | 2023-04-27 | — | — | WO | disclosed |
| CN-114788823-A | Biphenyl sulfonamide compounds for use in the treatment of renal diseases or disorders | 特拉维尔治疗公司 | 2022-07-26 | — | — | CN | disclosed |
| US-20210196688-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Travere Therapeutics, Inc. | 2021-07-01 | — | — | US | disclosed |
| EP-3708163-A1 | USE OF SPARSENTAN FOR THE TREATMENT OF CHRONIC INFLAMMATORY DISEASES | Ligand Pharmaceuticals, Inc. (US) | 2020-09-16 | — | — | EP | disclosed |
| EP-3222277-B1 | A BIPHENYLSULFONAMIDE ENDOTHELIN AND ANGIOTENSIN II RECEPTOR ANTAGONIST TO TREAT GLOMERULOSCLEROSIS AND IGA-INDUCED NEPHROPATHY | LIGAND PHARM INC (US) | 2020-02-26 | — | — | EP | disclosed |
| US-20190262317-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | Retrophin, Inc. | 2019-08-29 | — | — | US | disclosed |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2004-06-03 | — | — | US | disclosed |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | POLNIASZEK RICHARD P (US) | 2004-03-25 | — | — | US | disclosed |
| US-6638937-B2 | As antihypertensive agents; for therapy of disorders related to renal, glomerular and mesangial cell function; therapy of endotoxemia or endotoxin shock as well as hemorrhagic shock; useful in alleviation of pain associated cancer | BRISTOL-MYERS SQUIBB CO. | 2003-10-28 | — | — | US | disclosed |
| US-6639082-B2 | Cycloboronate intermediates; endothelin antagonists useful, inter alia, for the treatment of hypertension. | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-28 | — | — | US | disclosed |
| EP-1328523-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | Bristol-Myers Squibb Company (US) | 2003-07-23 | — | — | EP | disclosed |
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | PHARMACOPEIA, LLC | 2002-10-03 | — | — | US | disclosed |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | BRISTOL-MYERS SQUIBB COMPANY | 2002-09-19 | — | — | US | disclosed |
| EP-1237888-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2002-09-11 | — | — | EP | disclosed |
| WO-2002032884-A2 | METHODS FOR THE PREPARATION OF BIPHENYL ISOXAZOLE SULFONAMIDES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-04-25 | — | — | WO | disclosed |
| WO-2001044239-A2 | BIPHENYL SULFONAMIDES AS DUAL ANGIOTENSIN ENDOTHELIN RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB CO. (US) | 2001-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020143024-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | GAA 1248/4885HTT 2253/4885POLB 3365/4885 |
| US-20190262317-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, SULT2A1, ARSA | GAA 801/4885HTT 440/4885POLB 3167/4885 |
| US-20040106833-A1 | Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists | EDNRB, AGTR2, EDNRA | GAA 1248/4885HTT 2253/4885POLB 3365/4885 |
| US-20020132838-A1 | Methods for the preparation of biphenyl isoxazole sulfonamides | REN, STS, CYP4X1 | GAA 3464/4885HTT 2652/4885POLB 2251/4885 |
| US-20210196688-A1 | BIPHENYL SULFONAMIDE COMPOUNDS FOR THE TREATMENT OF KIDNEY DISEASES OR DISORDERS | REN, ATP6V1B1, VHL | GAA 183/4885HTT 223/4885POLB 4122/4885 |
| US-20040059123-A1 | Such as N-(methoxymethyl)-N-(4,5-dimethyl-3-isoxazolyl)-2-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl) benzenesulfanamide; endothelin antagonists for treatment of hypertension; high melting | EDNRA, EDNRB, ECE1 | GAA 4206/4885HTT 2401/4885POLB 3279/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.